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Barcelona Science Park
The Barcelona Science Park (PCB, Parc Científic de
Barcelona) is a cornerstone of the innovation system devel-
oped by the University of Barcelona (UB, Universitat de
Barcelona), with the support of the Bosch and Gimpera
Foundation (FBG, Fundació Bosch i Gimpera) and the Caixa
Catalunya, which hosts research groups from both the pub-
lic and private sectors and offers a wide range of technolog-
ical facilities.
The coming together of public research Centers and pri-
vate enterprise makes the PCB a pioneering point of refer-
ence in promoting the transfer of knowledge and technolo-
gy, and also facilitates the setting up of new
technology-based companies.
Situated on the Diagonal Campus, the Barcelona Science
Park hosts twenty companies, four research Centers, and
the CIDEM-PCB Bioincubator, all of which work in emerging
research areas of chemistry, pharmacy, biotechnology and
nanobioengineering. These research activities are located
in a 20,000 m2 laboratory building, which is also home mod-
ern platforms to R+D+I.
The PCB also brings together numerous research Cen-
ters from a wide range of areas in the experimental, human
and social sciences.
The aims of the PCB are:
• To create a context which optimises collaboration be-
tween public research groups and business R+D+I
units, thereby boosting technological innovation
through basic research.
• To play an active role in the technology market by in-
creasing the transfer of knowledge and technology to
companies and public institutions
• To promote the setting up of new technology-based
companies
• To support PCB researchers by providing them with the
most powerful biotechnology platforms, and to make
these services available to other external public re-
search groups, companies and organisations.
• To foster R+D+I activities in diverse multidisciplinary
fields in order to facilitate response to emerging eco-
nomic cycles
1. Public research at the Barcelona Science Park
The research carried out at the Barcelona Science Park is
multidisciplinary and covers an array of areas in experimen-
tal, human and social sciences. The result is the conver-
gence, in a single setting, of a critical mass of human re-
sources in areas linked to production sectors of special
relevance, thus contributing to greater economic and social
cohesion in the new knowledge-based economy.
Among the scientific areas to which the Park is devot-
ed, special mention should be made of the biomedical re-
search carried out by the Institute of Biomedical Research 
of Barcelona (IRBB-PCB), the Laboratory for Nanobioen-
gineering Research, and companies and spin-offs from 
the biotechnology, pharmaceutical and fine chemistry sec-
tors.
The shared aim of all the public research groups in the
PCB is to promote the transfer of knowledge and technolo-
gy, making a wide range of knowledge available to society
via, for example, the sub-contracting of research and/or ser-
vices, the development of mixed research units, the com-
mercialisation of patents or the setting up of technology-
based companies (spin-offs).
1.1 Institute of Biomedical Research of Barcelona
Research Programmes:
• Structural and Computational Biology Programme
• Chemistry and Molecular Pharmacology
• Molecular Medicine Programme
• Cell and Developmental Biology Programme
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Figure 1. PCB modular building.
1.2 Laboratory of Nanobioengineering Research 
(UB-UPC)
Research Programmes:
• Cellular and molecular nanotechnology
• Engineering of tissues and cell cultures
• Characterization of tissues and /or cell cultures
• Design of devices for the manipulation and processing
of cells and molecules on a chip(biochip/lab-on-a-chip)
• Acquisition and treatment of biomedical signals and
images
1.3 Center for Research in Theoretical Chemistry
Research areas:
• Chemical and biochemical reactivity
• Quantum simulation of biological processes
• Science of surfaces
• Interfacial and colloidal systems
• Macromolecules
• Design of new materials, etc.
1.4 Multidisciplinary groups
Research areas:
• Globalisation
• Bioethics
• Meteorology and climate
• Public Law
• Language and Computing
• Nutrition, etc.
2. Companies, business R+D+I units and spin-offs
The Barcelona Science Park is home to several companies
and spin-offs, all of which are linked to the priority research
lines of the Park. These companies benefit from a setting
with maximum research activity and a modern infrastructure
of support services.
The centralising of public research Centers and compa-
nies from the pharmaceutical, biotechnology and fine
chemistry sectors within the PCB brings basic research and
the discovery of new drugs closer together, thus fostering 
a synergistic relationship between the two poles. Such com-
bined efforts often lead to the setting up of mixed research
units.
2.1 Companies and spin-Offs
Advanced In Vitro Cell Technologies (Advancell)
Almirall Prodesfarma
Esteve
Grupo Uriach
Kymos Pharma Services
Medichem
Merck Farma y Química . Bioresearch Laboratory (LBI)
Prous Science . Prous Institute for Collaborative Research
(ICBR)
2.2 Companies occupying office space
Applera Hispania
Biolab
Bruker
Diopma
e-sense
Haltisform
Meteosim
Sani-red
Thera, Center for Language and Computation
2.3 Mixed units developed within the PCB
Almirall Prodesfarma– Barcelona Science Park
Pharma Mar– Barcelona Science Park
3. Entrepreneurial spirit and transfer of knowledge
3.1 Bioincubation
The main aim of the CIDEM-PCB Bioincubator is to facilitate
the creation of new biotech companies, by providing scien-
tific and technological support infrastructure, business man-
agement and financial assistance.
The maximum length of stay in the Bioincubator is three
years, during which time the companies receive financial
support from the Center for Innovation and Business Devel-
opment (CIDEM, Center d’Innovació i Desenvolupament
Empresarial) and the PCB. This initiative has been promoted
through the CIDEM, which belongs to the Autonomous Gov-
ernment of Catalonia (Generalitat de Catalunya), and by the
University of Barcelona, through the Barcelona Science Park
and the Center for Innovation (FBG).
3.2 Companies located at the CIDEM-PCB Bioincubator
• CrystaX Pharmaceuticals
• Enantia
• Era-Plantech
• Estralim
• Oleoyl-Estrone Developments OED
• Oryzon Genomics
3.3 The Center for Innovation
The Center for Innovation is part of the Bosch i Gimpera
Foundation (FBG) and aims to promote the transfer of
knowledge and technology from all areas of the University
of Barcelona to the business sector. Its activity ranges from
providing technological services and research projects 
to offering support in the creation of spin-offs. It also fos-
ters an enterpreneurial spirit through specific pro-
grammes which oversee and follow-up the work of research
groups.
In collaboration with the Patents Center of the UB, the
Center for Innovation is also responsible for promoting the
commercialization of the patents developed by the universi-
ty’s research groups.
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4. Technological facilities
Occupying an area of 5,000 m2, the technological facilities
available in the Barcelona Science Park include powerful in-
frastructure and specialized services which provide support
to researchers in the Center. In addition, these facilities are
also available to external institutions and companies.
Types of service:
• independent access to equipment
• consultancy service
• sub-contracting of services
4.1 Scientific and Technical Services of the UB
The Scientific and Technical Services (SCT) were set up by
the University of Barcelona to provide research support.
These services are staffed by specialized personnel and
have a modern infrastructure of high-tech apparatus. Occu-
pying 6,000m2, the SCT have three sites: the Modular Build-
ing of the Barcelona Science Park, a Central Building locat-
ed close to the experimental science faculties of the UB, and
the School of Medicine –near the facilities of the Institut d’In-
vestigacions Biomèdiques August Pi i Sunyer (IDIBAPS).
4.2 Units located in the PCB
• Nuclear Magnetic Resonance (NMR) Unit
• Unit for Separation Techniques
• Confocal Microscopy and Cellular Micromanipulation
Unit
• Flow Cytometry Unit
• Unit for in situ Molecular Recognition Techniques
• Genomics Unit
• Peptide Synthesis Unit
• SCT Quality Control Unit
4.3 Biotechnology Platforms SCT-PCB
A joint initiative between the Barcelona Science Park and the
SCT, the Biotechnology platforms are equipped with state-
of-the-art scientific instrumentation and carry out R+D activi-
ties in areas linked to the development of specific tech-
niques. These Platforms provide custom-designed research
services, a consultancy service, and co-development of
specific techniques; independent access to equipment can
also be arranged.
Platforms located in the PCB:
• Transcriptomics Platform
• Proteomics Platform
• Biocomputing Platform (Genoma España)
• Combinatorial Chemistry Platform
• Fine Chemistry Platform
• NMR Platform for Biomolecules
• Nanotechnology Platform
• X-Ray Diffraction Platform
5. Scientific Services of the PCB
The Services Services of the PCB provide support to re-
search managed by the Barcelona Science Park.
These Services Include:
• Animal Research Center (ARC)
• Core Scientific Services (SCC-PCB): Culture rooms,
centrifuge rooms, dark rooms, cold rooms, etc.
• Radioactivity Unit (IR-PCB)
• Unit for Experimental Toxicology and Ecotoxicology
(UTOX-PCB)
• Special Reactions Service (SRE-PCB)
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Figure 2. Combinatorial Chemistry Platform.
Figure 3. Proteomics Platform.
6. Brief history of the Barcelona Science Park
1994 The Board of Governors of the UB approves the pro-
vision of space for the creation of a science park.
1997 Creation of the Barcelona Science Park Foundation
by the UB, the FBG and the Caixa Catalunya. Collab-
oration agreement between the Autonomous Govern-
ment of Catalonia, the UB and UPC to promote the
Barcelona Science and Technology Park.
1998 The Central Government joins the agreement to set up
the Barcelona Science and Techology Park. Work be-
gins on the Modular Building and renovation of Tower D.
1999 The first office space for multidisciplinary research is
made available for the new head offices of the FBG
and its Innovation Center. Installation of the 800 MHz
NMR Spectrometer.
2000 Incorporation of the Scientific and Technical Services
of the UB into the Modular Building.
2001 Attended by 1,500 people, the Inaugural Scientific
Symposium of the Barcelona Science Park is held to
mark the completion of construction and the start-up
of the Biomedical Division. Incorporation of the first
companies and spin-offs from the industrial pharma-
ceutical and fine chemistry sectors.
2002 Public research groups working in biomedicine move
to the Institute of Biomedical.
Research of Barcelona, located in the Modular Build-
ing. The Scientific Support Services of the PCB and
the Biotechnological Platforms begin operating. The
CIDEM-PCB Bioincubator is opened.
2003 The Barcelona Biomedical Alliance is established
(ABB). The research groups that belong to the IBMB
of the CSIC join the IRBB-PCB. The Park works full
capacity.
392
PCB – Annual report 2002
Research activities in the PCB
With the incorporation of all the University of Barcelona (UB)
groups and the new ICREA (Institució Catalana de Recerca i
Estudis Avancats, Catalan Institute of Research and Ad-
vanced Studies) researchers, 2002 was the first year of full
research activity of the PCB. This implied the full operation of
all the scientific services as well as the start of the series of
seminars entitled “Park Seminars”. The opening conference,
on 17 January, 2003, was given by Dr. Jaume Piulats, Direc-
tor General of Merck, and was attended by the Rector of the
UB, Joan Tugores. The series of seminars was designed to
include one or two sessions per week and attendance was
very high. This series was sponsored by the Caixa Catalun-
ya bank.
In addition, and related to the promotional activities di-
rected at research, the summer of 2002 saw the start of the
programme “Spend the Summer at the Park”. This pro-
gramme, aimed at students in the last two years of their de-
gree, was designed to offer them the opportunity to carry out
research over the summer (July, August and September) in
groups working in their field of interest. In 2002, the pro-
gramme included 38 students (from a total of 51 applica-
tions) and was received with great enthusiasm both on the
part of lecturers and students.
We also wish to mention that the PCB participated in sev-
eral projects of the VI Framework Programme of the Euro-
pean Union, both as an institution as through the re-
searchers from Centers located in the Park.
Activities were the following:
• The PCB was one of the 20 institutions (Centro Na-
cional de Biotecnología (Madrid), Institut Pasteur
(Paris), Institut Karolinska (Stockholm), Genopôle-Evry
(Paris), Aventis Farma (Germany)...) that participated in
a European project for the training of graduate re-
searchers in biotechnology and pharmaceutical re-
search, ENAEBIP (European Network for Advanced
Education in Biotechnology and Industrial Pharmacy).
The Park participated by organizing practical courses
and workshops in proteomics, nanobiotechnology,
NMR, scientific communication and company founding
(given by the FBG).
• Through the Center de Referència en Bioenginyeria de
Catalunya (CREBEC, Catalan Reference Center for Bio-
engineering), the PCB participated in several initiatives
in the field of nanotechnology. We give special mention
to the Network of Excellence (Xarxa d’Excel·lència)
(Nano2life), which is the first step towards a Virtual Eu-
ropean Institute of Nanobiotechnology.
• Theoretical chemistry project (Dr. Carme Rovira, Ra-
mon i Cajal Researcher of the PCB, Center for Re-
search on Theoretical Chemistry)
• An extended version of this report is available in
www.pcb.ub.es
Modular building
Institute of Biomedical Research of Barcelona 
(IRBB-PCB)
Approved by the Board of Trustees on 27 February, 2001,
and directed by Dr. Joan Guinovart, with the scientific as-
sessment of Dr. Joan Massagué, the Institute of Biomedical
Research of Barcelona (IRBB-PCB) gave priority to the fol-
lowing objectives in 2002:
• Fitting out laboratories and setup of research infra-
structure provided by the PCB.
• Relocation of UB research groups in the PCB.
• Normalization of research activities in new laboratories.
• Promotion of groups (hiring researchers and support
staff).
• Applications to public calls for collaboration grants with
research groups.
• Incorporation of ICREA researchers.
These objectives were achieved progressively during the
first six months of 2002 and by the last three months of the
year all the groups were fully operational.
875 m2 of fully equipped laboratory space was assigned
to the CSIC. These laboratories were fitted out during 2002
and these research groups are to join the PCB in the second
half of 2003.
An indicator of the commitment of the DURSI to the pro-
motion of the IRBB-PCB is the UB-DURSI agreement, which
brought about an investment of 1M  for 2002.
This financial support was devoted basically to:
• Partially cover the costs of the first ICREA researchers
and UB investigators.
• Contract laboratory support technicians.
• Cover post-doctoral grants.
• Cover ordinary operational costs of the IRBB-PCB.
The IRBB-PCB is included in the framework of Centers
and institutes included in the III Research Plan of Catalonia,
and brings together groups of excellence from the UB, CSIC
and ICREA programme, all of which are devoted to fields
linked to basic biomedicine.
The IRBB-PCB is organised around four programmes,
which provide an ideal setting for the attainment of optimum
results. It has a dynamic structure that allows it to adapt to
the evolution of the field of study, thereby ensuring that its
activity is at the cutting edge of biomedical research.
In 2002, the programmes were as follows:
• Cell and Developmental Biology Programme
Gene expression. Developmental molecular biology.
Cellular biology, functional genomics and proteomics of
cell and embryonic development. Tissue regeneration.
• Developmental neurobiology and neuronal regener-
ation
• Structural and Computational Biology Programme
Structural analysis of macromolecular interactions. X-
ray, NMR and electronic microscopy platforms. Macro-
molecular biophysics. Structural biology and bioinfor-
matics of molecular modelling.
• Molecular recognition
• Protein NMR
• Molecular Medicine Programme
Molecular bases of metabolic and genetic diseases.
Study of diagnostic or therapeutic targets. Functional
genomics and proteomics of pathologies.
• Macrophage biology: regulation of gene expression 
• Metabolic engineering and diabetes therapy
• Molecular pathology and therapy in heterogenic and
polygenic diseases
• Molecular pathology and therapy in heterogenic and
multigenic diseases
• Signal transduction: interaction between nuclear
hormone receptors and pathways of mitogen-acti-
vated protein kinases (mapks)
• Chemistry and Molecular Pharmacology Programme
Design and synthesis of small molecules and macro-
molecules, with special emphasis on two aspects of
combinatorial chemistry: the building of libraries and
the optimisation of the production of synthetic com-
pounds. Biotechnologies for molecular selection di-
rected at therapeutic targets as well as at establishing
the relationship between drugs and their targets.
• Design, synthesis and structure of peptides and pro-
teins: molecular recognition 
• Peptidomimetics and bioactive heterocycles
(BIOSYNER)
• Combinatorial Chemistry for the development of new
compounds
• Research unit on asymmetric synthesis (URSA)
Catalan Reference Center for Bioengineering, (CREBEC).
Laboratory of Nanobioengineering
The Laboratory of Nanobioengineering, made up of re-
searchers from the UB and UPC, was set up as the result of
a collaboration agreement signed on 8 January, 2002, be-
tween the rectors of the same universities, with the aim to
promote interdisciplinary research in nanobioengineering.
The main research lines are as follows: cellular and molecu-
lar nanotechnology, the engineering of tissues and cell cul-
tures, characterization of tissues and/or cell cultures, the de-
sign of devices for the manipulation and processing of cells
and molecules on-a-chip, and the acquisition and treatment
of biomedical signals and images.
During 2002, Dr. Chris Hills signed a contract with the labo-
ratory, through the MCYT Ramon i Cajal Programme. With this
new incorporation, the laboratory now has four researchers
who have been contracted through the Ministry and who are
involved in several national and European Projects.
On 31 May, 2002, the Laboratory of Nanobioengineering
participated in the French/Spanish meeting on nano-sci-
ences and nano-technologies organised by the French Min-
istry of Research. With the aim to promote European re-
search into Nanbiotechnology, the Laboratory also
organised an Executive Meeting of the European Network of
Excellence: Nano2life, which was held in the PCB on 5 and 6
May, 2003.
Located in the Park since its setup and managed by the
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FBG, the laboratory is a key element of the Center de Refer-
ència en Bioenginyeria de Catalunya (CREBEC, Catalan
Reference Center for Bioengineering), which was approved
by the Generalitat de Catalunya in March 2003. This Center
aims to coordinate the activities linked to multidisciplinary
research in biomedical engineering carried out in Catalonia,
and is part of the recently approved “Special Action for the
Development of Nanoscience and Nanotechnology in Cat-
alonia”, promoted by the DURSI (DOGC nº 3867 del
17/04/2003).
Among the objectives of the CREBEC is the promotion of
the Laboratory of Nanobioengineering of the PCB, which
aims to become a pioneering biomedical research Center at
nanometric level.
Companies
At the closing date of this report, the companies located in
the Modular Building of the PCB were as follows:
• Advancell
• Almirall Prodesfarma
• Grupo Uriach*
• Kymos Pharma Services
• Medichem
• Merck Farma i Química
• Proteomika
• Prous Science
• Applied Biosystems
• Bruker
The only new incorporation in 2002 was the Grupo Uri-
ach, which occupies 50 m2 of office space in the Modular
Building. This company is Spain’s oldest pharmaceutical
laboratory and is a leader among pharmaceutical compa-
nies and one receptive to the most important technological
changes that will come with the new century. In February,
2002, Grupo Uriach opened a new work Center in Palau-
solità i Plegamans (a Catalan town). Thus, as a result of a
new strategic plan, which aims to strengthen the Drug Dis-
covery Unit, the company started a new period of expan-
sion and development in research into new molecules. As a
result of this strategy, a large part of the drug discovery
work is carried out via several collaborative projects with
prestigious university research groups and public and pri-
vate Centers. In this regard, the Grupo Uriach has set up
an R+D unit in the PCB, which enables a satellite team of
researchers to collaborate closely with the scientific pro-
jects that are being developed in coordination with the
PCB’s front line research.
Specifically, the Grupo Uriach has established collabora-
tive contracts with the IRBB-PCB research groups led by
Drs. Miquel Pons and Fernando Albericio, who are members
of the UB Department of Organic Chemistry. These agree-
ments are aimed at the development of research into new
therapeutic targets of interest with respect to asthma and the
application of advanced technology (high-field NMR) to syn-
thesize active molecules. Ongoing collaboration has also
been established with the Molecular Recognition Group of
the IRBB-PCB, led by Dr. Modest Orozco, and aimed at us-
ing advanced models of molecular modelling in the structur-
al design of new molecules and drug/receptor interactions.
Technicians of the Grupo Uriach also made periodic use of
the PCB’s scientific and technical services.
Mixed units and joint ventures
2002 has been a key year for establishing joint projects be-
tween PCB research groups, both public and private.
Among the most successful initiatives was the setup of
mixed units (between companies and research groups or
technology platforms of the PCB) and strategic agreements
between several companies.
We give special mention to the setup of a mixed unit for a
laboratory of Combinatorial Chemistry, a joint initiative be-
tween Almirall Prodesfarma (APF) and the PCB. In its 100
m2, the two institutions carry out research into the synthesis
of new compounds of interest to APF, through combinatorial
chemistry techniques. Under the scientific coordination of
Dr. Fernando Albericio of the IRBB-PCB, the researchers
from this laboratory perform many activities for the Combina-
torial Platform of the PCB. In 2002, two of the laboratory re-
searchers were contracted by the PCB through the MCYT
Torres Quevedo Programme for doctors (Dr. Pilar Forns and
Dr. Natàlia de la Figuera).
Along the same lines, a mixed laboratory between Phar-
ma Mar and the PCB was also set up in 2002. This unit de-
velops research projects jointly with Pharma Mar.
Similarly, as a the result of the synergy that has arisen
from their location on the same site, several companies in
the PCB established a series of strategic agreements. In ad-
dition, a number of companies signed agreements with
prestigious external companies from the pharmaceutical,
biotechnology and fine chemistry sectors.
Joint Ventures of the companies located in the PCB
30/05/2003 – The biotechnology company CrystaX signs
an agreement with Esteve to resolve the 
tridimensional structure of a neuronal re-
ceptor. This receptor is a therapeutic target
for drugs aimed at neurological diseases,
which are currently being developed by Es-
teve.
14/05/2003 – The pharmaceutical company Grupo Uriach
and the biotechnology company Oryzon Ge-
nomics sign a collaboration agreement
which will allow the Grupo Uriach to use ge-
nomic analysis tools in animal experiments in
its studies on new therapies for inflammatory
diseases. The application of this technology
plays a key role in the discovery, validation
and development of new drugs and uses,
among others, techniques with DNA chips
and bioinformatic analysis to predict the re-
sponse to and toxicity of candidate drugs.
30/04/2003 – DiverDrugs i Advancell amplien el seu acord
per al co-desenvolupament de nous compos-
tos neuroprotectors Advanced In Vitro Cell
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Technologies (Advancell) i DiverDrugs han
fet públic avui l’extensió del seu acord per
completar conjuntament les primeres fases
dels desenvolupament preclínic del progra-
ma de noves molècules neuroprotectores de
DiverDrugs que tenen potencials aplicacions
en malalties com Alzheimer, Parkinson o
Hungtington. L’ampliació de l’acord incorpo-
ra un nou candidat, el DD1012, al primer com-
post inclòs en el programa, el DD612. 
16/12/2002 – Oryzon Genomics and eBiointel sign a
strategic collaboration agreement for the de-
velopment of a new bioinformatic platform,
named ORYMOLD, which will allow the stor-
age and analysis of data related to genomic
processes.
15/11/2002 – The companies Medplant Genetics and Ad-
vancell announce an agreement for the de-
velopment and commercialisation of the first
platform in Spain that integrates cellular
models “in vitro” with analysis of changes in
genetic expression. The platform, called the
Toxicogeniomic Platform “in vitro”, aims to
predict hepatic, renal or cardiac toxicity of
new drugs and is aimed at the pharmaceuti-
cal and biotechnology sectors.
21/12/2002 – Advancell and DriverDrugs agree to develop
DiverDrug’s leading neuroprotector com-
pound, DD612. DiverDrugs will be responsi-
ble for completing the characterisation of the
mechanism of action of the compound and
the preliminary chemical and pharmaceuti-
cal development, while Advancell will carry
out the strategic and global management of
the work plan, including the search for phar-
maceutical partners to complete clinical de-
velopment. In addition, Advancell will per-
form basic tests on toxicity, metabolism and
distribution in vitro in its facilities in the PCB
and will outsource some of the services nec-
essary in order to complete the basic infor-
mation package that this co-development
aspires to produce.
31/10/2002 –Oryzon Genomics signs a strategic collabora-
tion agreement with the Institut de Recerca i
Tecnologia Agroalimentària (IRTA, Agroali-
mentary Research and Technology Institute),
which will involve a joint research programme
aimed at developing new plant varieties. The
agreement includes leading edge technology
for the drawing-up of genetic maps and for
the development of new plant varieties with
added value, and joint promotional projects.
The CIDEM-PCB bioincubator
In June 2002, the Generalitat de Catalunya and the UB
opened the first bioincubator in Spain. This facility is located
in the PCB and its the main goal is to provide scientific and
technological support infrastructure for new business pro-
jects in the biotechnology sector that have arisen from an
academic or business context (spin-offs). This initiative was
promoted through the Center d’Innovació i Desenvolupa-
ment Empresarial (CIDEM, Center for Innovation and Busi-
ness Development), which belongs to the Department of In-
dustry, Commerce and Tourism of the Generalitat de
Catalunya, and by the UB, through the PCB and the FBG.
The location of these Centers in the Park offers consider-
able advantages to initial-stage biotechnological companies
that join the CIDEM-PCB Bioinbubator. In this regard, they
save on the cost of their first premises, and also on costs of
acquisition and access to equipment, since the users of this
facility have access to the centralized research support ser-
vices of the PCB.
With a capacity for seven biotechnological companies, in
its first stage the Bioincubator occupies approximately 500
m2, distributed between seven laboratories of 50-75 m2 and
4-6 offices of 10-15 m2. The maximum time that a company
can be included in the project is three years, during which it
receives financial support from the CIDEM and the PCB.
At present the following companies are included in the
Bioincubator:
• CrystaX Pharmaceuticals
• Oryzon genomics
• Oleoyl-Estrone Developments (OED)
• ERA Plantech
• Estralim
• Enantia
CrystaX Pharmaceuticals is a state-of-the-art technology
company that focuses on the discovery and development of
new drugs. Founded by two researchers from the Universitat
Politècnica de Catalunya (UPC, Technical University of Cat-
alonia) and the Consejo Superior de Investigaciones Científi-
cas (CSIC, Spanish Council for Scientific Research), CrystaX
is currently working on the development of anti-cancer drugs
through the use of x-ray diffraction, which allows an enor-
mous reduction in the time required for research.
Oryzon genomics arose from the UB and the CSIC, and is
the first Spanish company devoted to the application of ge-
nomic techniques in plants. With the objective to increase
the annual production and quality of rice to satisfy present
day needs, this company has developed a new technique,
using DNA chips, to generate complete groups of genetic
mutations in rice in a short time, which is achieved through
modifying the genetic code. The results obtained can be ex-
trapolated to other cereals consumed by humans.
Oleoyl-Estrone Developments (OED) is a new company that
arose as a spin-off from the UB with the assistance of the
technology springboard of the same university. OED directs
its research effort towards drugs for the treatment of obesity
and associated diseases. Together with a North American fi-
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nancing company specialized in the pharmaceutical and
biotechnological industry, OED has founded a new enter-
prise, Manhattan Pharmaceuticals, which has its head of-
fices in New York. This company aims to promote the devel-
opment and international commercialisation of a new drug
against obesity based on Oleoyl Estrone.
ERA Plantech is a biotechnology company that arose from
the CSIC and is devoted to the production of peptides and
proteins of therapeutic or industrial interest in transgenic
plants. The company uses original and exclusive technology
(ZERA) (Zein Endoplasmic Reticulum Accumulation), which
allows the production of recombinant proteins through their
deposition on protein bodies of plant cells. This technology
has been successfully applied to produce calcitonin in to-
bacco plants. At present, ERA Plantech aims to validate and
optimise ZERA technology to ensure its viability and com-
petitiveness to produce a wide range of peptides and pro-
teins.
Estralim was founded in 2002 by Oleoyl-Estrone Develop-
ments and by Josep Sancho, professor of the UB Depart-
ment of Microbiology. This company develops procedures
for the removal of unwanted steroids from food and arose
from the discovery of the natural hormone oleoyl-estrone
(OE), which plays a key role in the regulation of body weight.
The observation that part of this hormone present in animals
is ingested through food, especially milk and dairy products,
has led Estralim to develop methods that remove OE and
that allow the production of dairy products that are not con-
tra-indicated for individuals with weight problems and/or hy-
percholesterolemia.
Enantia is a company of recent creation devoted to the syn-
thesis and development of chemical processes for the
preparation of chiral active pharmaceutical ingredients
(APIs) in enantiomerically pure form. The products and ser-
vices available include the development of original synthetic
processes for the preparation of chiral active pharmaceuti-
cal ingredients or intermediates in enantiomerically pure
form. Furthermore, Enantia also offers a catalogue of original
enantiomerically pure chiral products and libraries of com-
pounds that incorporate enantiomerically pure “building-
blocks” for pharmacological screening. Enantia provides
consultancy and technology transfer services in all stages of
development of a chemical process for manufacturing a
pharmaceutical ingredient, among others.
Scientific services of the Park
2002 was a key year in that it marked the full operation of the
diverse Scientific Services of the PCB. Of these, we highlight
the following:
Core scientific services (SCC-PCB)
The Core Scientific Services provide centralized installations
with modern research support equipment and experienced
personnel. These services became progressively opera-
tional throughout 2002, with the arrival of research groups to
the Modular Building.
During the first six months of 2002, at least one of the
rooms of each facility became operational (dark rooms,
spectroscopy room, cold chambers, centrifuge rooms,
freezer room, cryoconservation tanks and climatic chamber
(37ºC). May 2002 marked the start-up of the service for the
collection, cleaning/sterilization and return of material of the
distinct laboratories.
Regarding the Cell Culture Rooms located in the base-
ment, during the first half of 2002 construction work 
was completed (more than 150m2 of white room installa-
tions) and these rooms were then fitted out and validat-
ed. Furthermore, specific operational procedures were 
established for the management of waste products, use 
of equipment, maintenance and cleaning of the installa-
tions, assignation of work space, equipment maintenance
plan and registers and documentation in general. In Novem-
ber, this facility, designed for 18 people, was opened to
users.
To facilitate the use of equipment by UB researchers and
to deal with applications from potential users from other
companies or Centers, regulations for the use of these ser-
vices by external users was put on the PCB web site during
the second half of the year.
Throughout 2002, attention was focused on establishing a
management system for the SCC-PCB equipment and in-
stallations, with the aim to extend this system to other scien-
tific services (SEA-PCB and IR-PCB). By the year-end, a
computer programme had been chosen to build this system
and previsions were made for 2003 for the human and eco-
nomic resources necessary for its design, organization and
setup.
The actions defined for the SCC-PCB for 2003, in general
terms, were as follows:
• Operational setup of the Cell Culture Facility on the
ground floor.
• Adaptation of facilities to the needs of new public re-
search groups (not private).
• Application of a Quality Management system for equip-
ment.
• Continuous improvement of the service offered (appli-
cation of quality regulations, adaptation of equipment
and resources to users’ needs).
Animal Research Center (SEA-PCB)
After completing the construction work in the last three
months of 2001, the facilities and apparatus of the SEA-PCB
were tested, marking 2002 as the year in which the diverse
activities performed in this Center were consolidated and
the start of customer service. Similarly, during this year a
large part of the equipment for most of the SEA-PCB ser-
vices was acquired and the fine-tuning of the Transgenesis
Unit was performed. During the last three months of the year,
the first microinjections were done to generate the first re-
quest for an animal with transgenic overexpression. In addi-
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tion, the equipment for the cryopreservation laboratory, lo-
cated in the transgenesis unit, was purchased.
A large part of the studies carried out in the SEA-PCB dur-
ing 2002, were short-term and involved a large number of in-
coming and outgoing animals, but did not imply an increase
in the occupation of the animal house. With the entry of Ge-
netically Modified Organisms (GMO) at the end of the year,
long-term experimental procedures were started. Conse-
quently, in 2003 an increase in occupancy is expected for
breeding and maintenance of this kind of animals.
The animals housed in the SEA-PCB were basically ro-
dents (7 mouse rooms, 1 rat room and 1 guinea pig room),
the rat being the most used animal. Of the total number of
mice, GMOs accounted for 15 %. In addition, aquatic
species, Xenopus, were also kept in these facilities.
Of the private companies located in the PCB, the main
users of the SEA-PCB were Merck and Almirall Prodesfarma.
The use of the facilities by IRBB-PCB researchers was grad-
ual (specially during the last three months of 2002). External
companies also began to use the facilities for animal experi-
mentation.
All the procedural documents given to users were as-
sessed by the Animal Welfare Committee of the PCB. In De-
cember 2002, the Generalitat de Catalunya authorized all
the procedures presented by the PCB.
During 2002, several analytical microbiological controls
of surfaces and air quality were conducted. These controls
showed that there was no increase in microbiological agents
that could be a health risk. Similarly, in the health monitoring
of animals, no pathogen described in the FELASA recom-
mendations was detected.
During 2002 the first questionnaires were given to users of
this service. Analysis of the responses showed a global
mark of 3.72 and average of all the questions of 3.83 (out of
a maximum of 4).
Having completed several courses approved by the Gen-
eralitat de Catalunya and after one year of operational activi-
ty, the SEA-PCB staff is now fully trained in all the profession-
al categories within the field of animal research. We highlight
that users expressed a satisfaction rating with personnel of
4.05 out of 5.
For 2003, the SEA-PCB aims to:
• achieve international accreditation as a Center for ani-
mal experimentation (international AAALAC)
• organize a public presentation of the SEA-PCB for pro-
fessionals from this sector
• increase the offer of services (GMO generation, cryop-
reservation of embryos, surgical procedures, obtain
Xenopus embryos)
• start a line of research related to improving animal welfare.
Radioactivity Unit (IR-PCB)
At the beginning of 2002, all the facilities and annex systems
that make up the IR-PCB were fully equipped and prepared
for research activities involving radioactive material. Howev-
er, before the start of activity, to obtain the official authoriza-
tions, the installations had first to be inspected to test com-
pliance with technical requirements. This inspection was
carried out on 16 January, 2002, by the Dept. of Industry of
the Generalitat de Catalunya. The outcome of this inspection
was favourable for the start-up of the IR-PCB. Final notifica-
tion of the authorization for the beginning of activities was
sent on 27 February, 2002.
To grant authorization for the start-up of activities in the
IR-PCB, it was necessary to draw up a specific service con-
tract between the PCB and each research group wishing to
use this unit. During 2002, these contacts were formalized
as UB research groups and private companies began to
move into the PCB facilities. By the end of the year, most
groups using the IR-PCB had signed these contracts, which
were pending approval by the authorities.
In addition to research groups working in the PCB, a year
contract was established with the company Pharmamar,
which, in collaboration with the Combinatorial Chemistry Re-
search Group for the Development of New Compounds, led
by Dr. Fernando Albericio, was granted use of the IR-PCB
facilities and equipment. Furthermore, this unit also provided
its service periodically to external research groups, mostly
from the UB.
A total of approximately 53 people from distinct research
groups used the IR-PCB in 2002. Most of these individuals
(41) underwent dosimetric controls for external radiation
through TLD dosimeters provided by the Center for Dosime-
try, S.L. The results of these tests indicated that these users
had not absorbed radiation during this period.
Notwithstanding, all those who worked in the IR-PCB facil-
ities during 2002 had medical check-ups in the medical ser-
vices of a number of health insurance companies, depend-
ing on their contract. Each individual that handles
radioactive material in the IR-PCB is under the responsibility
of another member of his/her group who is a qualified Super-
visor or Operator of radioactive material in the IR-PCB. Dur-
ing this period a total of 9 Supervisors and 8 Operator licens-
es were given. This is still an insufficient number if one
considers the total number of people using the IR-PCB and
in the future the number of licenses will be increased
through Supervisor Courses organised by the PCB.
With respect to the radioactive material in liquid form, the
IR-PCB managed all the purchases, acquisition or transport
from other radioactivity installations of the material used dur-
ing 2002. Furthermore, the materials stored were maintained
at lower levels that those authorized.
Finally, radioactive waste generated by the activities car-
ried out in the IR-PCB is kept in a special store. Waste with a
short period of disintegration, such as P-32, P-33 and S-35,
is maintained in the store until its activity reaches limits per-
mitted by legisation to then be disposed of with normal
waste; while waste from isotopes with a longer period of dis-
integration is kept in the store until its removal by ENRESA.
Experimental Toxicology and Ecotoxicology Unit (UTOX-PCB)
In 2002 the UTOX-PCB consolidated technical and organi-
sational aspects, thereby completing its infrastructure, fine
Barcelona Science Park 397
tuning new techniques and progressing with the develop-
ment of its quality plan. The unit is now fully operational.
In addition to classic toxicological studies, the
UTOX–PCB offers a wide range of techniques, which, be-
cause they are new or provide added value from the techno-
logical point of view, define a clearly differential offer with re-
spect to other Toxicology Units in Spain. Among these
services are:
• Frog Embryo Teratogenesis Assay-Xenopus (FETAX)
• Local Lymphatic nodules assay (LLNA)
• Comet Test
• Identification of species in processed food
• Environmental field studies
In accordance with the objective of the PCB to foster syn-
ergies between groups and companies and promote interre-
lations between external research Centers and companies,
the UTOX-PCB is currently carrying out collaboration pro-
jects and drawing up study proposals, with the following,
among others:
• Companies in the Park
• Almirall Prodesfarma
• Merck
• Advancell
• Proteomika
• Research groups of the Park
• Combinatorial Chemistry
• Design, synthesis and structure of new proteins
• Park units or services
• Animal Research Center (SEA-PCB)
• Core Scientific Services
• External Companies
• Biotecnal
• Fardi
• Reig Jofré
• Mologen
• Aurum
• Uniland
As technical auditor of the UTOX-PCB, the Park signed a
contract with the Entidad Nacional de Acreditación (ENAC,
National Accreditation Agency) with respect to leading ser-
vices offered by this unit. The first audit to be undertaken un-
der this contact will be carried out at the beginning of July,
2003.
With respect to the research financed by public funds, the
members of this unit currently participate in two consultancy
agencies, they are partners in a project application to the
VIth Framework Programme of the European Union, will pre-
sent another application to the same programme and are
currently working on a possible participation in a project fi-
nanced by the European Center for the Validation of Alterna-
tive Methods.
Furthermore, the members of the UTOX–PCB participated
in the teaching of doctoral courses, thesis committees and
congresses. These activities included three conferences,
five oral presentations in congresses, a published article,
four articles in revision and four in preparation.
The UTOX-PCB also collaborated periodically in the re-
search activities of several UB groups (Departments of Mi-
crobiology, Animal Physiology, Cellular Biology and Animal
Biology – Vertebrates).
Special Reactions Service (SRE-PCB)
To support and facilitate the development of R+D+I projects
in the pharmaceutical sector and in fine chemistry, the PCB
set up a Special Reactions Service.
The general objectives of this new service, which is aimed
both at internal and external users and works on a self-ser-
vice basis, are as follows:
• To provide researchers in the PCB or external institu-
tions and companies with laboratories in which they
can perform experiments that involve a high risk or seri-
ous inconvenience to people working in the Park.
• To facilitate the development of R+D+I projects of re-
search groups and companies working in the PCB or
possible users from external Centers or companies that
require these facilities.
• To ensure the appropriate maintenance of the facilities
and equipment available to users.
This service has three laboratories:
• Laboratory for Toxic Products and hazardous reactions.
• Hydrogenation Laboratory
• Hydrofluoric Acid Laboratory.
The creation and operational setup of these laboratories
began in September 2002, after which, the activities fo-
cussed on:
• Adapting the installations to house the distinct labora-
tories.
• Forecasting the use that will be made of the service and
purchasing the equipment and material necessary.
• Establishing regulations for the use of the service and
corresponding charges.
• Ensuring the maintenance of the service and coordinat-
ing its use by researchers.
• Drawing up operation procedures for the service and
studying the charges applied for its use.
The laboratory for toxic products and hazardous reac-
tions became operational in February 2003.
Research support technology platforms
The biotechnology platforms are research support units for
biotechnology, biomedicine and fine chemistry. Located in
the PCB, these units comprise state-of-the-art equipment
and highly specialized technicians and provide the scientific
community, both public and private, with cutting edge tech-
nological services. The services of these platforms are of-
fered at a local, regional, and national level.
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The objective is to provide a quality service to users from
all the institutions that make up the UB Group, other universi-
ties, and public research Centers and companies, both in-
ternal and external.
The platforms are organized to offer:
• Specific periodic services.
• Consultancy service in the application of techniques.
• Rental of areas and equipment for use on a self-service
basis.
• Development and optimisation of techniques in order to
improve the applications of the equipment available.
• Support for scientific projects.
• Joint research projects in collaboration with the user.
At the time of this report, the Park had set up the following
platforms, some of which are managed jointly with the UB
Scientific and Technical Services:
• Transcriptomics Platform
• Proteomics Platform
• Biomolecular NMR Platform
• Combinatorial Chemistry Platform
• Fine Chemistry Platform
• Nanotechnology Platform
• X-ray Platform
The Transcriptomics and Proteomics Platforms became
fully operational during 2002. Both are headed by scientists
contracted by the PCB through the MCYT Torres Quevedo
Programme (Dr. Lidia Sevilla and Dr. Eliandre de Oliveira,
respectively). Similarly, Dr. Jesús Garcia, from the Biomolec-
ular NMR Platform, was contracted through the MCYT Ra-
mon y Cajal Programme.
Consolidated since 2001, the Combinatorial and Fine
Chemistry Platforms became fully operational in 2002.
The equipment to complete the Nantechnology and 
X-ray Platforms was purchased through a loan granted by
the MCYT in 2002. At the closing date of this report, the
Nantechnology Platform had started its activities under 
the leadership of Dr. Elena Martínez while the X-ray Plat-
form was pending installation of the latest equipment ac-
quired.
Department of Quality Assurance and Environmental Health
and Safety
At the start of 2002 the Department of Quality Assurance and
Environmental Health and Safety (QSMA) was consolidated
with the incorporation of a head of department and a part-
time accident prevention officer.
The main activities of this department during 2002 were:
1. Regarding Quality:
• Drawing-up and approval of work procedures for
the scientific services of the PCB promoted at the
beginning of 2002.
• The beginning of 2003 marked the drawing-up of
the main procedures in management areas of the
Park: Purchasing, Maintenance, QSMA, Administra-
tion and Organization, Computer Systems and Com-
munications, etc.
2. Regarding Safety
• Drawing-up and application of an Emergency Plan
for the Modular Building. First evacuation drill in May
2003.
• Initial risk assessment of all work areas of PCB staff.
• Follow-up and coordination with each group or com-
pany of the risk assessment of work areas.
• Training of new researchers through a twice-yearly
course on laboratory safety. 130 researchers had
completed this course at the closing date of this re-
port.
• Specific sign posting and provision of safety equip-
ment for common use.
3 Regarding the Environment
• Collection of standard waste.
• Collection of non-standard waste that is not generat-
ed by laboratories. This group includes cardboard,
glass, toners and batteries.
• Optimisation of the collection and later management
of laboratory waste.
• Promotion of the campaign to save water and light in
areas of shared use.
All the measures taken by this department can be con-
sulted at www.pcb.ub.es/qsma. This web page also pro-
vides information on current legislation on the sector and
technical information of interest.
Tower D and the Florensa Building
During 2002 the following groups, companies and services
set up offices in Tower D and the Florensa Building:
TOWER D
• Fundació Bosch i Gimpera
• Euroregional Photovoltaic Systems Group
• Linguistic Advice Service
• Center for the Evaluation and Prospects of Research
and Innovation
• Patent Center of the University of Barcelona
• Center for Research in Welfare Economics
• Center for Social and Educational Research
• Center for Research in Theoretical Chemistry
• Food Studies Group
• Climatology Group
• Meteorology Group
• Conservation Biology Group
• Climate Research Group
• Logic, Language and Cognition Research Group
• Nutritional Research group
• Institute of Public Law
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• Observatory of Bioethics and Law
• Sani-Red
FLORENSA BUILDING
• Research Center on Citizenship and Civil Society
• Center of Studies on Changes in Culture and Education
• Film-History Research Center
• Center for the Design and Optimisation of Processes
and Materials
• Computer Linguistics Center
• Center for Languages and Computation
• Research Center on Regional, International and Risk
Economics
• University Center on Sociolinguistics and Communica-
tion
• Division I, Human and Social Sciences of the UB
• Family and Kinship Research Group
• Research Group on Computational Linguistics
• Research Group on Ageing
• Inland Waters Research Group
• HOMINID – Study Group on Human Origins
• Barcelona Institute of Economics
• Intercultural Ethics Observatory
• Globalisation Observatory
• Medamerica Network
In 2002, the Observatory of Tibet and Central Asia, one of
the multidisciplinary groups of the Park, provisionally worked
from an annex of the Modular Building.
The PCB continued its relationship with the Research Cen-
ter on Women’s Studies, located in the Faculty of Philosophy.
Similarly, the PCB continued it efforts to promote and pro-
vide equipment to the documentation Centers located in the
Library Building of the UB:
• Documentation Center for Plant Biodiversity (Ce-
DocBiV)
• Sabater Pi Collection
The decision to incorporate groups into the PCB is taken
on the basis of the development of research activities and
the transfer of this scientific activity to society and to the
business sector. The activity and continuity of research
groups, Centers and institutes in the Park, depends on
favourable periodic assessment of their research. On the
one hand, groups must provide yearly information on the ac-
tivities carried out in order to ensure that the level of re-
search excellence; a requirement for Centers with analogue
characteristics located in the PCB. In this way, the standards
of the PCB will not fall below those of others Centers world-
wide. In addition, extensions require a formal, independent,
external evaluation of the activities.
In the meeting of the Advisory Council of the PCB held on
9 April, 2002, the research groups located in Tower D and
the Florensa Building were informed of the evaluation that
would be done that year.
On completion of this annual report, the first evaluation of
the users of the PCB had been finished. The methodology
followed was:
• Scientific development of groups. Analysis of the inputs
and outputs according to the Curriculum Vitae included
in the database of the Vice-rectorate of Research of the
UB of all the members holding a Ph.D. This database may
be complemented by personnel from all kinds of public
or private organisations that operate from the PCB.
• Evaluation of a report that lays out the transfer activities
undertaken, the activities that have given value added
through the presence of the groups in the PCB, the im-
portance in the sector and other merits considered rel-
evant.
Documentation Centers
Documentation Center for Plant Biodiversity
October 1 marked the opening of the Documentation Center
on Plant Biodiversity (CeDocBiV). The act included the par-
ticipation of Walter G. Berendsohn, Professor of the Botanis-
cher Garten und Botanisches Museum Berlin-Dahlem (Freie
Universität Berlin), who gave a conference entitled “Biologi-
cal collections: an essential component of the global biodi-
versity information infrastructure”.
The opening was presided by Antoni Juárez, UB Vice-
Rector of Research and second Vice-President of the PCB,
and was attended by Màrius Rubiralta, Director of the PCB,
Josep Vigo, Director of the Research Center on Plant Biodi-
versity, Julià Molero, Director of the CeDocBiV, and Dolors
Lamarca, Director of the UB Library.
The CeDocBiV is part of the UB Research Center on Plant
Biodiversity (CERBIV) and holds the documentation that its
researchers produce. The CeDocBiV aims to promote re-
search on plant biodiversity and its applications by facilitat-
ing access of researchers, companies and society at large
to its documentation, by either direct or virtual means.
The CeDocBiV occupies 300 m2 in the PCB, which in-
clude the BCN Herbarium, a sample preparation facility and
work area equipped with technical equipment. The BCN
Herbarium, the third largest in Spain, is the result of the join-
ing of the Herbarium of Division III with that of the UB Faculty
of Pharmacy. The Herbarium holds approximately 300,000
specimens, mainly from the Iberian Peninsula and other
Mediterranean areas, which are grouped into five documen-
tation sections (cormophytes, lichens, fungi, algae and
bryophytes).
The CeDocBiV also includes data bases which have pro-
duced several documental units related with biology and taxa
distribution, plant mapping, cytogenetics, etnobotany, phy-
tocenology and bibliography related to plant biodiversity.
In addition to consultation of the reference collections in
the CeDocBiV, the Center also offers a specimen lending
and exchange service with other herbaria, an advisory ser-
vice on plant identification, information on the distribution of
plant species and communities and specialised courses.
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The Jordi Sabater Pi Collection
In 2002 the Sabater Pi Collection, which is of great interest to
scientists and academics in anthropology, ethology and his-
tory, and the general public, was extended. This collection is
composed of books and journals on topics related to etholo-
gy, drawings and paintings of naturalistic subjects, most of
which were done by Jordi Sabater Pi himself. The collection
also includes a professional epistolary and a series of ob-
jects from Africa which show the culture and lifestyle of the
people, and the animals there. The collection is housed in
the library of the Faculty of History and Geography of the UB,
in space managed by the PCB.
February 20, 2003, marked the presentation of the book
“Primates. Origin, Evolution and Behaviour” published by
the PCB in honour of the ethologist Jordi Sabater Pi. The
event was attended by Jordi Sabater Pi, Màrius Rubiralta,
Director General of the PCB, Joaquim J. Veà, professor of
the Department of Psychiatry and Psychology of the UB and
Jordi Serrallonga, Director of HOMINID-Study Group on Hu-
man Origins. During the presentation the Special Center for
Primate Research of the UB was also presented. This Center
promotes research in fields such as primate palaeontology,
physical anthropology, biomechanics, and the evolution and
molecular reconstruction of primates, among others.
“Primates. Origin, Evolution and Behaviour” includes con-
tributions from prestigious names in anthropology, archaeol-
ogy and biology, such as J. Desmond Clark, Jonathan King-
don, Owen Lovejoy, Frank E. Poirier, Philip V. Tobias and
Juichi Yamagiwa. These presentations were given in 1997 in
an event organised by the UB Vice-rectorate for Research in
honour of Sabater Pi. The publication of the book was coor-
dinated by Joaquim J. Veà, and Jordi Serrallonga and also
by Josep Maria Fullola, from the Department of Prehistory,
Ancient History and Archaeology, Daniel Turbón, from the
Department of Animal Biology, and David Serrat, from the
Department of Geodynamics and Geophysics, all of the UB.
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